Award to xlcare pharmaceuticals for methocarbamol tablets for the base year with four one-year options.

Active Indefinite Delivery Contract Awarded Last action

Contract number
36E79724D0018
Awardee
Awarding agency
Task orders
0

Award facts

Opportunity
Last date to order 87% complete
IDV ceiling
$11,608,273.60
Award type
Single award
Set-aside
No set-aside
Competition
Full and Open Competition · 8 offers Negotiated Proposal / Quote
Pricing
Firm Fixed Price

Award details come from SAM.gov/FPDS.

About this IDV

The National Acquisition Center awarded an indefinite-delivery contract to Xlcare Pharmaceuticals Inc. for methocarbamol tablets on March 23, 2024, with a ceiling of $11,608,273.60. This is a single-award contract with no set-aside designation.

Xlcare Pharmaceuticals Inc. is an economically disadvantaged woman-owned small business and registered minority-owned, small disadvantaged business.

The contract supplies methocarbamol tablets in 500mg and 750mg strengths to the Department of Veterans Affairs, Department of Defense, Bureau of Prisons, Indian Health Service, and Federal Health Care Center. Annual requirements total over 15,000 bottles of 500mg tablets and over 10,000 bottles of 750mg tablets, with estimated annual quantities ranging from approximately 15,000 to 96,000 bottles depending on item and strength.

The originating solicitation (36E79724R0005) required offerors to hold a unique NDC number and specify the exact drug name to be supplied. NAICS code 325412 applies.

The contract runs for a one-year base period from the March 23, 2024 award date through March 22, 2027, with four one-year option periods. The contract implements Executive Order 14398 on diversity, equity, and inclusion.

Transactions

Action Obligated Date
Supplemental Agreement for work within scope P00004 · Implementing EO 14398 DEI discrimination $0
Exercise an Option P00003 · Exercise option year 2 for methocarbamol tablets. Period of performance 3/23/2026 - 3/22/2027. $0
Exercise an Option P00002 · Exercise option year 1 for methocarbamol tablets. Period of performance 3/23/2025 - 3/22/2026. $0
Supplemental Agreement for work within scope P00001 · Update to cost recovery fee (CRF) and submission of quarterly sales reports $0
Original award $0

Quick answers

Who was awarded contract 36E79724D0018?

36E79724D0018 was awarded to Xlcare Pharmaceuticals Inc. by National Acquisition Center (Headquarters) on March 23, 2024.

How much is contract 36E79724D0018 worth?

36E79724D0018's own ceiling is $11,608,274.

Who can order from contract 36E79724D0018?

36E79724D0018 is a single award indefinite delivery contract.

Was contract 36E79724D0018 competed?

The extent of competition for 36E79724D0018 was full and open competition. The government received 8 offers.

On GovTribe

See this IDV's full record

  • Every order and transaction
  • The awardee's other awards and teaming partners
  • Similar IDVs and recompete opportunities
  • Ask GovTribe AI about this IDV